New hope for cervical cancer patients when standard immunotherapy stops working
NCT ID NCT05824468
Summary
This study is testing whether a combination of two drugs, zimberelimab and lenvatinib, can help control advanced cervical cancer that has continued to grow despite prior immunotherapy. It aims to see if this combination is safe and effective for up to 30 women whose cancer has progressed after standard treatments. The goal is to find a new treatment option for patients who have run out of other approved choices.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Cetntre
Guangzhou, 510060, China
Conditions
Explore the condition pages connected to this study.